## Teresa Guerrero Urbano

## List of Publications by Citations

 $\textbf{Source:} \ https://exaly.com/author-pdf/8660423/teresa-guerrero-urbano-publications-by-citations.pdf$ 

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27 1,552 12 28 g-index

28 1,853 4.6 3.8 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
27	Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 127-36	21.7	1106
26	Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. <i>Human Gene Therapy Clinical Development</i> , <b>2013</b> , 24, 134-42	3.2	88
25	MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 1021-34	7.5	69
24	A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 85, 36-41	5.3	42
23	Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 85, 58-63	5.3	40
22	Analysis of loco-regional failures in head and neck cancer after radical radiation therapy. <i>Oral Oncology</i> , <b>2015</b> , 51, 1051-1055	4.4	35
21	(18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1239-47	8.8	28
20	Osteoradionecrosis following treatment for head and neck cancer and the effect of radiotherapy dosimetry: the Guy's and St Thomas's And Neck Cancer Unit experience. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology,</i> <b>2016</b> , 122, 28-34	2	26
19	New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors. <i>Oral Oncology</i> , <b>2017</b> , 67, 119-123	4.4	17
18	Presenting pre-radiotherapy dental status of head and neck cancer patients in the novel radiation era. <i>British Dental Journal</i> , <b>2020</b> , 228, 435-440	1.2	16
17	Gastrostomy versus nasogastric tube feeding for chemoradiation patients with head and neck cancer: the TUBE pilot RCT. <i>Health Technology Assessment</i> , <b>2018</b> , 22, 1-144	4.4	13
16	Radical (chemo)radiotherapy in oropharyngeal squamous cell carcinoma: Comparison of TNM 7th and 8th staging systems. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 145, 146-153	5.3	12
15	Multicentric human papillomavirus-associated head and neck squamous cell carcinoma. <i>Head and Neck</i> , <b>2015</b> , 37, 202-8	4.2	12
14	Pre-radiotherapy presenting dental status of the three most common head and neck cancer subsites in a novel radiation era. <i>Faculty Dental Journal</i> , <b>2020</b> , 11, 52-57	0.6	12
13	Radiotherapy quadrant doses in oropharyngeal cancer treated with intensity modulated radiotherapy. <i>Faculty Dental Journal</i> , <b>2020</b> , 11, 166-172	0.6	7
12	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
11	Controversies in small cell carcinoma of the head and neck: Prophylactic cranial irradiation (PCI) after primary complete initial remission. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 725-8	14.4	4

## LIST OF PUBLICATIONS

10	18F-FDG-PET in guided dose-painting with intensity modulated radiotherapy in oropharyngeal tumours: A phase I study (FiGaRO). <i>Radiotherapy and Oncology</i> , <b>2021</b> , 155, 261-268	5.3	4
9	Analyzing oropharyngeal cancer survival outcomes: a decision tree approach. <i>British Journal of Radiology</i> , <b>2020</b> , 93, 20190464	3.4	3
8	Systemic therapy for advanced basal cell carcinoma. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 608-10	21.7	3
7	Comparison of machine learning methods for prediction of osteoradionecrosis incidence in patients with head and neck cancer. <i>British Journal of Radiology</i> , <b>2021</b> , 94, 20200026	3.4	3
6	Biphenotypic human papillomavirus-associated head and neck squamous cell carcinoma: a report of two cases. <i>Diagnostic Pathology</i> , <b>2015</b> , 10, 97	3	2
5	A method for accurate spatial registration of PET images and histopathology slices. <i>EJNMMI Research</i> , <b>2015</b> , 5, 64	3.6	2
4	Pre-radiotherapy dental status of oropharyngeal cancer patients based on HPV status in a novel radiation era. <i>British Dental Journal</i> , <b>2020</b> ,	1.2	2
3	Risk stratified follow up for head and neck cancer patients - An evidence based proposal. <i>Oral Oncology</i> , <b>2021</b> , 119, 105365	4.4	1
2	Dentoalveolar radiation dose following IMRT in oropharyngeal cancer-An observational study. <i>Special Care in Dentistry</i> , <b>2021</b> , 41, 319-326	1.7	О
1	Should the HPV positive oropharyngeal cancer patient be considered for a two-stage dental assessment for their radiation treatment?. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 164, 232-235	5.3	